In a report released today, Jacob Johnson from Stephens maintained a Hold rating on CryoPort (CYRX – Research Report), with a price target of $15.00. The company’s shares closed today at $13.65.
Johnson covers the Healthcare sector, focusing on stocks such as Catalent, Steris, and BioLife Solutions. According to TipRanks, Johnson has an average return of 8.6% and a 42.50% success rate on recommended stocks.
Currently, the analyst consensus on CryoPort is a Moderate Buy with an average price target of $19.67.
See today’s best-performing stocks on TipRanks >>
Based on CryoPort’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $62.82 million and a GAAP net loss of $5.57 million. In comparison, last year the company earned a revenue of $52.3 million and had a GAAP net loss of $13.4 million
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYRX in relation to earlier this year. Most recently, in May 2023, Robert Stefanovich, the CFO of CYRX sold 19,918.00 shares for a total of $437,000.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.
Read More on CYRX:
